These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 31.07.2020 and posted on 03.08.2020by Cesar Mendoza-Martinez, Alejandro Rodriguez-Lezama, Norma Galindo-Sevilla, Fernando Cortés-Guzmán, Jessica Hernandez-Pineda, Abril Nieto-Lara, Francisco Hernandez-Luis
There is an urgency of finding molecules
available to treat Leishmaniasis, which is one of the significant issues of
health in undeveloped countries. For that reason is needed to explore molecular
diversity to find novel scaffolds. Fluorinated and adamantane derivatives exhibit
a formidable starting point. They are proved to improve the antileishmanial
activity when attached to molecules already active as we have shown in this
paper. Particularly fluorinated methoxy and ethoxy derivatives can increase its
volume depending on the number of fluorine, a unique behaviour that can be
exploited for molecular drug design purposes.